Development of Aripiprazole as an oral treatment of schizophrenia required the synthesis of a suitably labeled drug product for use in human metabolism and pharmacokinetic studies. Due to the potential metabolic degradation of the molecule, a multi-labeled approach utilizing 14C was adopted. The synthesis of [14C]Aripiprazole was accomplished in separate syntheses from 2,3-dichloro[U-14C]aniline and [3-14C]-cinnamic acid, respectively. Labeled versions were combined on the basis of molar radioactivity giving a final product with a radiochemical purity of 99.9% and a specific activity of 15.5 µCi/mg. Copyright © 2005 John Wiley & Sons, Ltd.
阿立哌唑作为精神分裂症口服治疗药物的开发需要合成适当标记的药物产品,用于人体代谢和药代动力学研究。由于该分子可能发生代谢降解,因此采用了利用 14C 的多标记方法。 [14C]
阿立哌唑的合成是分别从2,3-二
氯[U-14C]
苯胺和[3-14C]-
肉桂酸的单独合成中完成的。标记版本根据摩尔放射性进行组合,得到放射
化学纯度为 99.9%、比活度为 15.5 µCi/mg 的最终产品。版权所有 © 2005 约翰·威利父子有限公司